Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Portal Monaco.
Press releases published on June 2, 2025
Mimecast Partners with Zscaler to Mitigate Multi-Vector Cyber Threats
GlobeNewswire
·
June 2, 2025
LEXINGTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mimecast, a global cybersecurity leader transforming the way businesses manage and secure human risk, today announced a new strategic integration with Zscaler™. Building on Mimecast’s extensive library of …
Plotly Unveils AI-Native Plotly Studio™ and Plotly Cloud™, Bringing Vibe-Coding to Visual Data App Development
GlobeNewswire
·
June 2, 2025
MONTREAL, June 02, 2025 (GLOBE NEWSWIRE) -- Plotly today announced Plotly Studio™, an AI-native desktop application that automatically generates beautiful visual data apps in just two minutes using nothing but datasets, alongside Plotly Cloud™, a unified …
Crusoe Appoints John Michael Adams as Senior Vice President of Power Infrastructure to Accelerate On-Site Energy Development for AI Data Centers
GlobeNewswire
·
June 2, 2025
DENVER and SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- Crusoe, the industry’s first vertically integrated AI infrastructure provider, today announced the appointment of John M. Adams as Senior Vice President of Power Infrastructure. Adams will lead …
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
GlobeNewswire
·
June 2, 2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, …
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
June 2, 2025
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in …
Bitmine Immersion Technologies, Inc. Announces Uplist to NYSE American Stock Exchange
GlobeNewswire
·
June 2, 2025
LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Bitmine Immersion Technologies, Inc. (OTCQX: BMNRD) (“Bitmine” or “Company”), a technology company focused on Bitcoin mining using immersion technology, today announced that it expects its shares of common stock …
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
June 2, 2025
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …
CareCloud to Present on AI Innovation at Maxim Group’s 2025 Virtual Tech Conference on June 3, 2025
GlobeNewswire
·
June 2, 2025
Somerset, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-driven healthcare technology solutions for medical practices and health systems nationwide, announced today that its Co- …
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 2, 2025
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule …
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
GlobeNewswire
·
June 2, 2025
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: …
Plum Wins Gold at the 5th Annual 2025 Globee® Awards for Disruptors
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Revolutionary pre-hire assessment provider Plum is proud to announce that it has been named a winner of the Gold Technology Industry Disruptor at the 5th Annual 2025 Globee® Awards for Disruptors, a prestigious …
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
GlobeNewswire
·
June 2, 2025
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in …
Denodo University Challenge Now Open: Data and AI for Real-World Impact
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced that the Denodo Academic Program, which prepares students to become future leaders in the field of data and analytics, has opened registration for the next …
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire
·
June 2, 2025
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
GlobeNewswire
·
June 2, 2025
- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …
SAIC Announces First Quarter of Fiscal Year 2026 Results
GlobeNewswire
·
June 2, 2025
Revenues of $1.88 billion; approximately 2% revenue growth Net bookings of $2.4 billion; book-to-bill ratio of 1.3 Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues Diluted earnings per share of $1.42; Adjusted diluted …
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
GlobeNewswire
·
June 2, 2025
BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co- …
Conscio Technologies lance une offre de sensibilisation à la cybersécurité dédiée aux professionnels de l’assurance
GlobeNewswire
·
June 2, 2025
Conscio Technologies, spécialiste de la sensibilisation à la cybersécurité, annonce la création d’une offre dédiée aux acteurs de l’assurance et notamment la mise à disposition d’un contenu spécifique sur la réglementation DORA. Le secteur des assurances …
Curevo Enrolls First Participants in Phase 2 Extension Trial
GlobeNewswire
·
June 2, 2025
SEATTLE, June 02, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the enrollment of the first …